STING agonist therapy has been shown to reduce tumor development and increase intratumoral type I IFN production in several mouse tumor models10,17,18, though often the induction of type I IFN is also associated with increased expression of checkpoint markers62,63 and thus an elevated immunosuppressive tumor microenvironment. The gene discussed is STING1; the disease is neoplasm.